Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson ’s Disease

ConclusionsThese analyses provide further evidence supporting ADS-5102 as an adjunct to levodopa for treating both dyskinesia and OFF time in PD patients with dyskinesia.Clinicaltrials.gov identifier: NCT02136914 and NCT02274766

Source: CNS Drugs - March 12, 2018 Category: Neurology Source Type: research